Disclosures for "Barriers to participation in a prospective clinical trial for schwannomatosis-related pain")
-
Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.
-
Jennifer Da has nothing to disclose.
-
The institution of Vanessa Merker has received research support from Children's tumor foundation . The institution of Vanessa Merker has received research support from NF Northeast. Vanessa Merker has received personal compensation in the range of $10,000-$49,999 for serving as a science writer with Neurofibromatosis Network.
-
Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Navio Theragnostics. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Recursion Pharmaceuticals, Inc. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for Guidepoint. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for Atheneum Partners. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CEC Oncology. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for EM Partners. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for GLG. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Texas Health Resources. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Recursion Pharmaceuticals. Dr. Jordan has stock in Navio Theragnostics. Dr. Jordan has stock in The Doctor Lounge. The institution of Dr. Jordan has received research support from The Burke Foundation. The institution of Dr. Jordan has received research support from NIH. The institution of Dr. Jordan has received research support from Department of Defense. Dr. Jordan has received publishing royalties from a publication relating to health care. Dr. Jordan has a non-compensated relationship as a board member with United Council for Neurologic Subspecialties that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a board member with Neurofibromatosis Northeast that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a board member with ABA Academy that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a chair, scientific advisory board with Neurofibromatosis Network that is relevant to AAN interests or activities.
-
An immediate family member of Dr. Ly has received personal compensation for serving as an employee of Enanta Pharmaceuticals. Dr. Ly has received research support from Department of Defense. An immediate family member of Dr. Ly has received intellectual property interests from a discovery or technology relating to health care.
-
Alona Muzikansky has nothing to disclose.
-
Dr. Parsons has received publishing royalties from a publication relating to health care.
-
Dr. Wolters has stock in Bristol-Myers-Squibb. The institution of Dr. Wolters has received research support from Neurofibromatosis Therapeutic Acceleration Program.
-
lei xu has nothing to disclose.
-
Dr. Brown has received personal compensation for serving as an employee of Pfizer Inc. Dr. Brown has received stock or an ownership interest from Pfizer Inc.
-
Scot Styren has nothing to disclose.